In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

On Tuesday, U.S. Senator Mike Braun (R-Ind.) questioned Novo Nordisk CEO Lars Fruergaard Jørgensen at the Senate Health, ...

A Senate committee hearing this week once again delved into the issue of high-priced prescription drugs – in this case, one ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...